Which patients with COPD need an inhaled corticosteroid?

Area of Science:

• Pulmonology
• Respiratory Medicine
• Pharmacology

Background:

• Inhaled bronchodilators are a cornerstone treatment for all chronic obstructive pulmonary disease (COPD) patients.
• Clinical guidelines suggest inhaled corticosteroids (ICS) for specific COPD patient subgroups.
• These subgroups include those with eosinophilic COPD phenotypes, frequent severe exacerbations, or comorbid asthma.

Purpose of the Study:

• To delineate the patient profiles within chronic obstructive pulmonary disease (COPD) who are most likely to benefit from inhaled corticosteroid (ICS) therapy.
• To provide clarity on the conditional recommendations for ICS use in COPD management.

Main Methods:

• Review of clinical practice guidelines and relevant literature.
• Analysis of evidence supporting the use of inhaled corticosteroids (ICS) in different chronic obstructive pulmonary disease (COPD) phenotypes.
• Identification of patient characteristics associated with positive ICS response.

Main Results:

• Inhaled bronchodilators are universally recommended for COPD.
• Inhaled corticosteroids (ICS) show conditional benefit in COPD patients with eosinophilic phenotypes.
• ICS are also recommended for COPD patients experiencing hospitalizations or frequent severe exacerbations, and those with asthma.

Conclusions:

• The decision to use inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) should be individualized based on specific patient criteria.
• ICS are particularly beneficial for COPD patients with eosinophilic inflammation or a history of severe exacerbations.
• Co-existing asthma may also indicate a role for ICS in COPD management.